PURCHASE, NY, July 22, 2008 – Nutrition 21, Inc. (Nasdaq: NXXI) a developer and marketer of nutritional supplements that help consumers manage blood sugar levels, improve cardiovascular health, enhance memory and address chronic joint pain, today announced its agreement with Walgreens to supply three new chromium picolinate products for the Finest Natural® retail brand and one product for the Walgreens Gold Seal Private Label. These products are anticipated to be available late this summer or early fall.

Walgreens, one of the largest retailers in the United States, has 6,300 stores in 49 states. "Walgreens commitment is a major milestone in our move to expand our retail nutrition supplement business by working with industry-moving retailers to meet the growing needs of health-conscious consumers," said Michael Fink, co-Chief Operating Officer of Nutrition 21. "It also reflects the growing appreciation by retailers of Nutrition 21’s continuing commitment to develop and market proprietary and clinically substantiated nutraceuticals that address significant health care concerns. We anticipate beginning to receive revenues from these new products during the quarter ending September 30, 2008."

About Nutrition 21
Nutrition 21, Inc. (NASDAQ: NXXI), headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21’s portfolio of health and wellness brands include: Chromax®,  Core4Life Advanced Memory Formula™, Diabetes Essentials™, Iceland Health® Maximum Strength Omega-3 and Iceland Health® Joint Relief. The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 29,000 major food, drug and super center retailers as well as internationally.  For more information please visit http://www.nutrition21.com.
# # #

Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K/A for the year ended June 30, 2007. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.